细胞病理学中可靶向突变当日分子检测:快速现场评估的新前沿
该研究评估将Idylla超快速卡盒式检测系统作为细胞学快速现场评估(ROSE)延伸的可行性,对非小细胞肺癌、甲状腺癌和黑色素瘤标本进行试点验证,检测KRAS、EGFR、BRAF、基因融合及ALK、ROS1、RET、NTRK1/2/3和MET外显子14跳跃转录本的表达失衡。共测试144个卡盒检测,平均出结果时间2-3小时,KRAS和BRAF准确率100%,EGFR和GeneFusion准确率94%,分析灵敏度1%-5%变异等位基因频率,批间精密度和分析特异性均为100%。结论为可在细胞学和小活检样本中可靠检测可操作遗传变异,支持将当日分子检测纳入ROSE流程。
要点
- Idylla系统可在2-3小时内从细胞学和小活检样本中检测可操作遗传变异。
- KRAS和BRAF检测准确率100%,EGFR和GeneFusion检测准确率94%。
- 分析灵敏度为1%-5%变异等位基因频率,批间精密度和分析特异性均为100%。
核心结论
- 使用Idylla系统可在2-3小时内从细胞学和小活检样本中可靠检测可操作遗传变异,所需输入量极少。
- 研究证明将当日分子检测作为ROSE程序的一部分纳入细胞病理实验室是可行的,可缩短从操作到个体化治疗的时间。
研究设计与样本
- 试点验证研究,评估Idylla系统作为细胞学ROSE延伸的性能特征和周转时间。
- 标本来自非小细胞肺癌、甲状腺癌和黑色素瘤,共测试144个卡盒检测,涵盖细针穿刺涂片、FFPE细胞块、小组织活检FFPE块和对照细胞系FFPE卷片。
- 评估四种卡盒检测KRAS、EGFR、BRAF、基因融合及ALK、ROS1、RET、NTRK1/2/3和MET外显子14跳跃转录本的改变。
主要发现
- 从标本输入到结果输出的平均时间为2-3小时。
- 四种卡盒检测的准确率分别为:KRAS检测100%、EGFR检测94%、BRAF检测100%、GeneFusion检测94%。
- 所有检测的分析灵敏度范围为1%至5%变异等位基因频率。
- 批间精密度和分析特异性均为100%。
关键数值与推荐
- KRAS检测准确率100%,EGFR检测准确率94%,BRAF检测准确率100%,GeneFusion检测准确率94%。
- 分析灵敏度为1%-5%变异等位基因频率,批间精密度100%,分析特异性100%。
- 平均周转时间为2-3小时。
临床怎么用
- 可将Idylla系统作为ROSE的延伸,在细胞病理实验室实现当日分子检测。
- 适用于非小细胞肺癌、甲状腺癌和黑色素瘤的细胞学及小活检样本,检测可操作遗传变异。
- 有助于缩短从操作到个体化治疗的时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This study aimed to assess the feasibility of implementing the Idylla system, an ultra-rapid, cartridge-based assay, as an extension of rapid on-site evaluation (ROSE) in cytology. The authors conducted a pilot validation study on specimens from non-small cell lung carcinoma, thyroid carcinoma, and melanoma, evaluating four assays designed to detect alterations in KRAS, EGFR, BRAF, gene fusions, and expression imbalances in ALK, ROS1, RET, NTRK1/2/3, and MET exon 14 skipping transcripts. They investigated the feasibility of providing accurate biomarker molecular testing results in a cytopathology laboratory within hours of specimen collection. METHODS: The authors evaluated the performance characteristics and turn-around-time of the Idylla system by testing a total of 144 cartridge assays across various specimen types, including fine-needle aspirate smears, formalin-fixed paraffin-embedded (FFPE) cell blocks, small tissue biopsy FFPE blocks, and control cell line FFPE scrolls. RESULTS: The average time from specimen input to results output was 2-3 hours. Accuracy across the four cartridge types was: KRAS assay: 100%, EGFR assay: 94%, BRAF assay: 100%, and GeneFusion assay: 94%. Analytical sensitivity ranged from 1% to 5% variant allele frequency for all assays. Inter-assay precision and analytical specificity were both 100%. CONCLUSION: Using the Idylla system, actionable genetic alterations can be reliably detected within 2-3 hours from cytology and small biopsy samples with minimal input requirements. The findings of this study demonstrate the feasibility of incorporating same-day molecular testing as part of ROSE procedures in the cytopathology laboratory, ultimately shortening the time from procedure to personalized treatment for cancer patients.
引用
- Iorgulescu JB, Yang RK, Roy-Chowdhuri S, et al. Same-day molecular testing for targetable mutations in solid tumor cytopathology-The next frontier of the rapid on-site evaluation. Cancer Cytopathol. 2025. PMID: 39746874. doi:10.1002/cncy.22930
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。